Average Price Target: $45.50
▲ +83.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $45.50, with a high forecast of $47.00 and a low forecast of $44.00. The average price target represents a 83.91% upside from the last price of $24.74.
The current consensus among 3 polled investment analysts is to buy stock in 4D Molecular Therapeutics.
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.